

## E-Content

IFTM University, Moradabad

# PRE-FORMULATION Part 1

Dr. Vijay Sharma

## Content

- > Introduction to the Industrial Pharmacy.
- > Introduction to Preformulation.
- > Goals and objectives (Major area of preformulation research)
- Study of Physico Chemical Characteristics of Drug
   Substances

#### **INTRODUCTION**

- Prior to development of a formulation or dosage form, it is essential that certain properties of a drug molecule are to be determined.
- This information decides many of the subsequent events and approaches in formulation development.
- Preformulation is the phase of research and development in which the physical and chemical properties of a drug molecule is studied in order to develop safe, effective and stable dosage form.
- Preformulation commences when a newly synthesized drug shows a sufficient pharmacological promise in animal model to warrant evaluation in man.
- It is the First step in rational development of a dosage form of a drug substance.

3/2/2023

RPF02T/Hnits

#### **GOALS & OBJECTIVES**

- \*To generate information useful to the formulation in developing most stable and bioavailable dosage form that can be produced.
- \*To Establish necessary physico chemical parameters of new drug substance that can affect the drug performance and development of an efficacious stable and safe dosage form.
- Establish physical characteristics.
- Establish compatibility with common excipients.
- Provide insights into how drug products should beprocessed and stored to ensure their quality.
- To develop an optimal drug delivery system.

3/2/2023

- I. Compound Identity:
- II. Structure:
- III. Formula and Molecular Weight:
- IV. Therapeutic Indication:

Probable Human Dose: Desired Dosage Form(s): Bioavailability Model(s): Competitive Products:

- V. Potential Hazards:
- VI. Initial Bulk Lots:

Lot Number: Crystallization Solvent(s): Particle Size Range: Melting Point: % Volatiles: Observations:

#### VII. Analytical Methods:


HPLC Assay: TLC Assay: UV/VIS Spectroscopy: Synthetic Route: Probable Decay Products:

#### VIII. Key Dates:

Bulk Scale-Up: Toxicology Start Date: Clinical Supplies Preparation: IND Filing: Phase I Testing:

#### IX. Critical Development Issue(s):

Essential requirement helpful in designing Preformulation



#### PHYSICO-CHEMICAL CHARACTERISATION

#### A. Physical Properties of Drug Substances

- Organoleptic Characterisation
- Bulk Characterisation
- Solubility Profile

#### B. Chemical Properties of Drug Substances

- Hydrolysis
- Oxidation
- Reduction
- Racemisation
- Polymerisation

#### A. PHYSICAL PROPERTIES OF DRUG SUBSTANCES

- The physical properties of drug molecules can affect the structure and stability of formulations and may also alter the bioavailability of the drugs from the dosage forms.
- Hence, physical properties of drugs are important in the dosage form design.
- There are three categories of physical properties influence dosage form design.
- Organoleptic Characterisation
- Bulk Characterisation
- ✓ 3/2/2 Solubility Profile

#### i) Organoleptic Characterisation

Refers to the evaluation of drug on the basis of

- 1. Color,
- 2. Odor,
- 3. Texture and
- 4. Taste.
- Product should be good in appearance.
- Colour should be eye appealing.
- Odour and taste should be pleasant.
- Absence of impurities and should be in the purest form.

2*/2/2*022

DDEO2T/ LInit

#### ii) Bulk Characterisation

Bulk characterisation of drug molecules involves the characterisation of various solid – state properties that could change during the process development.

Variability of bulk characterisations, significantly prove subsequent events and approaches in drug development process.

#### **Bulk Characterization includes**


- >Crystallinity, Amorphism, and Polymorphism physical properties
- > Hygroscopicity
- > Fine particle characterisation
- Density (Bulk density)

## Crystallinity, Amorphism, and Polymorphism – Physical properties

#### 1. Crystallinity

- Crystal compounds are characterised by repetitious spacing of constituent atoms or molecules.
- Crystals can be of different shapes. E.g cubic, tetragonal, orthorhombic etc.
- The crystal habit and crystal internal structure of a drug can affect the bulk and flow properties as well as chemical stability.
- -Crystal habit outer appearance of a crystal

## CRYSTAL HABIT




## 1. CRYSTALLINITY

- \*Internal structure molecular arrangement within the solid.
- Degree of crystallinity affects the hardness, density, transparency, and diffusion.
- Crystallinity has a greater affect on the absorption of drugs.
- Crystalline compounds may have
  - \*stoichiometric or
  - ❖non stoichiometric adduct,


Where the non-stoichiometric adduct is undesirable and removed.

## INTERNAL STRUCTURE



## 2. AMORPHISM

- Amorphous compounds are those whose atoms or molecules are randomly placed.
- Internal structure shows a major distinction whether the solid is crystalline or amorphous.
- Some drugs can exist in amorphous state. They are typically prepared by rapid precipitation, lyophilization.
- Such drugs represent highest energy state, or higher thermodynamic energy than the crystalline state.
- Amorphous form are less stable than its crystalline state.
- The solubility of amorphous form is greater than its crystalline state.
- Upon storage, amorphous solids tend to revert to more stable forms. Thermodynamic instability is a major disadvantage for developing a dosage form.
  BP502T/ Unit-I



Amorphous structure of a glassy solid (left) and lattice structure of a crystalline solid (right).

### 2. POLY-MORPHISM

- When a substance exists in more than one crystalline form
- The different forms are designated as Polymorphs and theis phenomenon is known as Polymorphism.
- Polymorphs are of two types
- **Enantiotropicpolymorphs** is the one which can be reversibly changed into another form by altering the temperature or pressure.
- Monotropic polymorphs is the one which is unstable at all temperatures and pressures.
- -Polymorphs differ from each other respect to their physical properties like solubility, melting point, density etc.
- -Depending on the stability on enantiotrops will be more stable than the other. Such stable forms have lower energy state, high melting point, least aqueous stability.
- Other forms are called metastable forms with the opposite properties.
- -Determined by Differential Scanning Calorimetry, X –Ray Diffraction methods.

  BP502T/ Unit-I




Fig. 2.4: X-Ray Diffractograms of Different Forms of Solids

## Pseudo-polymorphs (Hydrate/ Solvates)

- Pseudo-polymorphism is also a known phenomenon in which two compounds exhibit different crystalline structures, of which one is the host of solvent molecules.
- A **hydrate** is a substance that contains <u>water</u> or its constituent elements.
- The chemical state of the water varies widely between different classes of hydrates, some of which were so labeled before their chemical structure was understood.

BP502T/ Unit-I

## References

#### **Reference Books**

- Leon Lachman, Liberman. The theory and practice of Industrial pharmacy, Edn 4. CBS publishing house, New Delhi.2013 p:217-307.
- Banker GS, Rhodes CT. Modern pharmaceutics, Edn 4. Marcel Dekker, New York. 2002 p:167-184.
- Loyd V. Allen, Nicholas G.popovich, Howard C. Ansel. Ansel's pharmaceutical Dosage forms & Drug delivery systems, Edn 8. B.I.Publication pvt. Ltd, p:187-193,42 & 43,126-133.

#### **Text Books**

- Leon Lachman, Liberman. The theory and practice of Industrial pharmacy, Edn 4. CBS publishing house, New Delhi.2013 p:217-307.
- Brahmankar D.M., Jaiswal S.B., First edition, "Absorption of Drugs" Biopharmaceutics and Pharmacokinetics – A treatise, Vallabh Prakashan, Delhi 1995.

# Thank You